Recent Finacing
Recent Raise
Artax Biopharma is a Cambridge clinical-stage biotech developing oral Nck-targeting small molecules (AX‑158/AX‑024) that selectively modulate T-cell receptor signaling for T cell–mediated autoimmune diseases, with Phase 1/2 trials.
